Outstanding questions on HIV vaccine trial [2] (multiple letters)

Science

Volumn 305, Issue 5681, 2004, Pages 180-

  Jefferys, Richard ^a   Harrington, Mark ^a   McNeil, John G ^b   Johnston, Margaret I ^b   Tramont, Edmund C ^b   Birx, Deborah L ^c  

^a Treatment Action Group   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALVAC; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFECTION PREVENTION; LETTER; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; VACCINATION;

AIDS VACCINES; ANIMALS; CLINICAL TRIALS, PHASE III; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; THAILAND; UNITED STATES; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 3042842775     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (0)